Ixekizumab May Prevent Reactivation of Tuberculosis in Patients With Latent Tuberculosis Infection

Ixekizumab May Prevent Reactivation of Tuberculosis in Patients With Latent Tuberculosis Infection

Publication date: Jul 17, 2020

Ixekizumab, and other antibodies that target interleukin 17 monoclonal antibody (IL-17A), may reduce reactivations of tuberculosis in patients with .. .

Concepts Keywords
Antibodies Monoclonal antibodies
Interleukin Tuberculosis
Monoclonal Antibody Immunosuppressants
Tuberculosis Immune system
Ixekizumab
Antibody
Latent tuberculosis
IL17A
Antibodies
Immunology
Medicine
Medical specialties

Semantics

Type Source Name
drug DRUGBANK Ixekizumab
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH Latent Tuberculosis Infection

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *